Latest News for KNBWY
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kirin (KNBWY) could produce exceptional returns because of its solid growth attributes.
Kirin (KNBWY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for KNBWY.
Senate Trading
No Senate trades found for KNBWY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.